ArticleClinical chemistry2014
Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood.
Article in Clinical chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 58 citations in OpenAlex.
- Advancing Leukemia Management Through Liquid Biopsy: Insights into Biomarkers and Clinical Utility.Cancers · 2025Review
- Microfluidic Technologies in Advancing Cancer Research.Micromachines · 2024Review
- On-Chip Magnetic Extraction of Circulating Cell-Free DNA from Biological Samples.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Dielectrophoresis: An Approach to Increase Sensitivity, Reduce Response Time and to Suppress Nonspecific Binding in Biosensors?Biosensors · 2022Review
- Analytics in Microfluidic Systems.Advances in biochemical engineering/biotechnology · 2022Article
- Current status of ctDNA in precision oncology for hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021Review
- Dielectrophoresis: Developments and applications from 2010 to 2020.Electrophoresis · 2021Review
- Direct electrophoretic microRNA preparation from clinical samples using nanofilter membrane.Nano convergence · 2020Article
- Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform.Frontiers in bioengineering and biotechnology · 2020Article
- Microfluidic Technologies for cfDNA Isolation and Analysis.Micromachines · 2019Review
- Raman spectroscopic evaluation of human serum using metal plate and 785- and 1064-nm excitation lasers.PloS one · 2019Article
- The Omics Revolution Continues: The Maturation of High-Throughput Biological Data Sources.Yearbook of medical informatics · 2018Review
- Magnetic Nanowire Networks for Dual-Isolation and Detection of Tumor-Associated Circulating Biomarkers.Theranostics · 2018Article
- A Whole Blood Molecular Signature for Acute Myocardial Infarction.Scientific reports · 2017Article
- Interference-Free Detection of Genetic Biomarkers Using Synthetic Dipole-Facilitated Nanopore Dielectrophoresis.ACS nano · 2017Article
- Dielectrophoresis for Biomedical Sciences Applications: A Review.Sensors (Basel, Switzerland) · 2017Review
- Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip.Oncotarget · 2017Article
- Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons.Current colorectal cancer reports · 2016Article
- Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.Cancer biology & medicine · 2016Article
- Dielectrophoretic recovery of DNA from plasma for the identification of chronic lymphocytic leukemia point mutations.International journal of hematologic oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCirculating cell-free DNA (ccf-DNA) is becoming an important biomarker for cancer diagnostics and therapy monitoring. The isolation of ccf-DNA from plasma as a "liquid biopsy" may begin to replace more invasive tissue biopsies for the detection and analysis of cancer-related mutations. Conventional methods for the isolation of ccf-DNA from plasma are costly, time-consuming, and complex, preventing the use of ccf-DNA biomarkers for point-of-care diagnostics and limiting other biomedical research applications.
methodsWe used an AC electrokinetic device to rapidly isolate ccf-DNA from 25 μL unprocessed blood. ccf-DNA from 15 chronic lymphocytic leukemia (CLL) patients and 3 healthy individuals was separated into dielectrophoretic (DEP) high-field regions, after which other blood components were removed by a fluidic wash. Concentrated ccf-DNA was detected by fluorescence and eluted for quantification, PCR, and DNA sequencing. The complete process, blood to PCR, required <10 min. ccf-DNA was amplified by PCR with immunoglobulin heavy chain variable region (IGHV)-specific primers to identify the unique IGHV gene expressed by the leukemic B-cell clone, and then sequenced.
resultsPCR and DNA sequencing results obtained by DEP from 25 μL CLL blood matched results obtained by use of conventional methods for ccf-DNA isolation from 1 mL plasma and for genomic DNA isolation from CLL patient leukemic B cells isolated from 15-20 mL blood.
conclusionsRapid isolation of ccf-DNA directly from a drop of blood will advance disease-related biomarker research, accelerate the transition from tissue to liquid biopsies, and enable point-of-care diagnostic systems for patient monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.